融券方面，当日融券卖出0.00万股，净买入0.05万股。 8月11日，沪深两融数据显示，华大基因获融资买入额0.39亿元，居两市第1197位，当日融资偿还额0.59 亿元，净卖出1994.48万元。 最近三个交易日，7日-11日，华大基因分别获融资买入0.93亿元、0.83亿元、0.39亿元。 ...

日本生育率暴跌，连科技都快被逼疯：大阪大学团队正在研发用皮肤或血液细胞制造精子和卵子的技 术，预计7年后女性生娃可能不需要男人。这究竟是怎么一回事？ ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 不同尺度的生物结构无缝整合以执行基本功能。尽管已开发出多种组织学方法来揭示这些复杂的结构，但在保持大体积架构完整性的同时以高分辨率揭示微观结 构，仍是一项重大挑战。 2025 年 8 月 11 日，清华大学生物医学工程学院 苑克鑫 教授团队在国际顶尖学术期刊 Cell 上发表了题为： VIVIT: Resolving trans-scale volumetric biological architectures via ionic glassy tissue 的研究论文。 该研究首次提出并验证了一种全新的生物组织处理方法—— VIVIT ， 实现了组织在玻璃态下的高保真三维成像 。VIVIT 同时突破了组织透明化领域的三个技术瓶 颈：透明与无形变不能同时实现、荧光信号衰减、不兼容无损冷冻保存与切片，为包括脑科学在内的基础研究、病理分析、AI 辅助诊断等应用打开了新的空间。 在这项最新研究中，研究团队开发了 基于玻璃态离子液体溶剂的全尺度生物结构三维成像技术 （VIVIT） ，这是一种利用离子液体化学特性的三维组织学方法， 首次实现了将不透光的生物 组织 在低温下转变为 ...

Group 1 - The company and its subsidiaries have recently obtained 25 overseas certifications and 2 authorized patents, enhancing its product offerings and intellectual property protection [1] - The acquisition of these qualifications responds to overseas market demands, improving the company's market expansion capabilities and core competitiveness [1] Group 2 - The company will continue to increase investment in product research and development, aiming to launch products that significantly contribute to human health and life [2]

Investment Rating - The report maintains a "Buy" rating for the company, with target prices adjusted to $18 for US shares and HK$28 for Hong Kong shares, reflecting a potential upside of 10% and 19% respectively [8][20]. Core Insights - The company's revenue from three core products significantly underperformed expectations in the first half of 2025, primarily due to intensified competition in the Chinese market. Consequently, the annual revenue guidance for the oncology segment has been revised downward [1][5]. - The report highlights that the overall oncology revenue for 1H25 was $143 million, down 14.9% year-over-year and 26.3% quarter-over-quarter, which was below both the report's and market expectations [5][8]. - The company is expected to achieve a revenue range of $127 million to $207 million in the second half of 2025, with management expressing confidence in potential sales growth due to new approvals and market penetration [5][8]. Financial Performance Summary - The company reported a net profit of $455 million in 1H25, which was slightly better than expectations, primarily due to cost savings in R&D and administrative expenses [5][8]. - Revenue projections for 2025, 2026, and 2027 have been adjusted to $575 million, $657 million, and $794 million respectively, reflecting a year-over-year decline of 8.8% in 2025, followed by growth in subsequent years [9][11]. - The report indicates that the company is considering introducing external oncology assets to enhance its pipeline, leveraging its strong cash reserves [7][8]. Market Expectations - The report outlines optimistic and pessimistic scenarios for the company's future performance, with target prices of $25 and $10 under different market conditions [24][30]. - The potential catalysts for the next 12 months include new drug approvals and submissions, which could significantly impact revenue growth [7][8].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price adjusted to USD 46 for the US stock and HKD 36 for the Hong Kong stock, reflecting potential upside of +35% and +18% respectively [5][13]. Core Insights - The company's Q2 2025 performance was below expectations, primarily due to lower-than-expected revenues from key products Aigamod and Zelek, as well as a decline in gross margin [1][2]. - Total revenue for Q2 2025 was USD 110 million, including product net revenue of USD 109 million, which represents a year-over-year increase of 9.0% but is significantly below market expectations [2]. - The net loss narrowed to USD 40.73 million, a decrease of 49.3% year-over-year, but still fell short of internal forecasts [2]. - The report highlights that Aigamod's sales were USD 26.5 million in Q2 2025, showing a year-over-year increase of 14.3%, but the growth rate has slowed compared to previous quarters [3]. - Zelek's revenue was only USD 41 million, down 8.8% year-over-year, attributed to increased competition from generic drugs [3]. Financial Performance Summary - The company maintained its full-year guidance for 2025, projecting total revenue between USD 560 million and USD 590 million, with expectations of significant growth in the second half of the year [4]. - The report anticipates that Aigamod will benefit from new treatment guidelines, potentially leading to a recovery in sales growth [4]. - The company is expected to face challenges in achieving its revenue targets, with projected growth rates of 63%-77% year-over-year and 59%-73% quarter-over-quarter for the second half of 2025 [4]. - Key catalysts for growth include updates on the promising pipeline product ZL-1310 and potential approvals for other drugs in the pipeline [4][12]. Market Data - The current stock price is USD 34.1, with a 52-week range of USD 16.0 to USD 44.3, and a total market capitalization of USD 3.747 billion [5]. - The average daily trading volume over the past three months is USD 32 million [5].

个股方面，药明康德涨2.37%，美团跌1.32%，阿里巴巴涨1.89%，建设银行跌1.12%，山东黄金跌 7.99%，紫金矿业跌0.87%，小鹏汽车涨5.36%，蔚来涨2.62%，赣锋锂业涨20.91%，天齐锂业涨 18.19%，汇量科技涨7.55%，老铺黄金跌5.48%，国泰君安国际跌1.37%，工商银行跌1.30%。 成交额前三的个股中，腾讯控股收平，成交超65亿港元；小米集团跌0.88%，成交超64亿港元；中芯国 际涨0.08%，成交超52亿港元。 （文章来源：新华财经） 新华财经香港8月11日电（记者林迎楠）11日港股主要指数高开低走，截至收盘，恒生指数上涨0.19% 至24906.81点，恒生科技指数下跌0.01%至5460.02点，国企指数下跌0.08%至8888.08点。 当日恒指低开87.73点，早段曾转跌，其后再度回稳，恒生指数涨47.99点，主板成交超2009亿港元。截 至收盘，上涨股票1223只，下跌946只，收平990只。当日，港股通（南向）净流出超过3834万港元。 整体来看，多数板块上涨，生物科技、券商、创新药、锂电池等股多为上涨，科网、房地产、新能源车 企等股有涨有跌，黄金、芯片 ...

Group 1 - The core viewpoint of the article highlights the financial performance and market activity of BGI Genomics Co., Ltd. as of August 11, 2025, showing a decline in revenue and net profit compared to the previous year [1] - As of the latest quarterly report, the company reported total revenue of 672 million yuan, a year-on-year decrease of 18.18%, and a net profit attributable to shareholders of 52.6951 million yuan, down 524.87% [1] - The company's liquidity ratios are strong, with a current ratio of 2.854 and a quick ratio of 2.617, while the debt-to-asset ratio stands at 26.68% [1] Group 2 - BGI Genomics has made investments in 71 companies and participated in 42 bidding projects, indicating active engagement in business expansion [2] - The company holds a significant intellectual property portfolio, with 665 trademark registrations and 375 patents, along with 14 administrative licenses [2]

IPO Pipeline Overview - As of August 10, there are 299 companies in the IPO pipeline, with 29 on the Shanghai Main Board, 36 on the Sci-Tech Innovation Board, 26 on the Shenzhen Main Board, 29 on the ChiNext, and 179 on the Beijing Stock Exchange [1][2]. Newly Listed Companies - From August 4 to August 10, three companies were newly listed: - Hansan (Nanjing) Technology Co., Ltd. on the ChiNext with a closing price of 82.89 CNY per share, a rise of 186.72%, and a trading volume of 2.048 billion CNY [4][5]. - Yangzhou Tianfulong Group Co., Ltd. on the Shanghai Main Board with a closing price of 56.80 CNY per share, a rise of 140.68%, and a trading volume of 1.971 billion CNY [5]. - Jiangsu Youli Intelligent Equipment Co., Ltd. on the Beijing Stock Exchange with a closing price of 83.22 CNY per share, a rise of 246.89%, and a trading volume of 732 million CNY [5]. New Counseling Record Companies - Eight companies were newly recorded for counseling from August 4 to August 10, including: - Beijing Jichuang Beifang Technology Co., Ltd., focusing on integrated circuit design [6][7]. - Yao Mazi Food Co., Ltd., specializing in seasoning products [8]. - Changde New Material Technology Co., Ltd., engaged in resource utilization and new materials [8]. - Anhui Jiren Pharmaceutical Co., Ltd., focusing on modern traditional Chinese medicine [8]. - Dongguan Yuanli Optoelectronics Co., Ltd., specializing in LCD backlight modules [8]. - Zhongdao Optoelectronic Equipment Co., Ltd., focusing on detection equipment for displays and solar cells [8]. - Tianbo Intelligent Technology (Shandong) Co., Ltd., producing various automotive sensors [9]. - Zhongxing Micro Technology Co., Ltd., providing video technology solutions based on AI and big data [9]. Approval Status of Companies - Three companies successfully passed the review process from August 4 to August 10: - Zhongcheng Zhixin Engineering Consulting Group Co., Ltd. on the Beijing Stock Exchange [10]. - Suzhou Fengbei Biotechnology Co., Ltd. on the Shanghai Main Board [10]. - Zhuhai Nante Metal Technology Co., Ltd. on the Beijing Stock Exchange [10]. - The review for Jiejia Robot Co., Ltd. was canceled [10]. Registration Approval - Two companies received registration approval from August 4 to August 10: - Guangzhou Bibete Pharmaceutical Co., Ltd., focusing on innovative drug development [16][17]. - Daming Electronics Co., Ltd., specializing in automotive electronic components [18]. Termination of Review - Only one company, Wenduoli Sunshade Materials (Dezhou) Co., Ltd., withdrew its IPO application during this period [20][21].

张凌表示，欧洲已不再是Biotech等生物科技融资的热门区域，很多欧洲企业更倾向去美国融资，甚至 有不少大型药企如 阿斯利康等，考虑将上市地区，从伦敦转去美国。 不过他也提到一个值得关注的趋势，在过去一到两年，企业首选美国，目标进入美国资本市场，做 Crossover融资，甚至部分公司为了在美上市而转移注册地。 据瑞恩小编统计，今年(截至8月11日)香港新上市的55家中，14家来自医疗健康行业、占比25.5%。 来源：MoneyDJ 花旗集团投资银行医疗健康部亚太区主管 (Managing Director, Head of Asia Pacific Healthcare Investment Banking at Citigroup)张凌(Ling Zhang)周一(8月11日)在亚太生物科技投资论坛上表示，欧洲 生物科技融资热度下降，企业首选是去美国以及亚太市场，十二个月以前首选都是美国，但过去六个月 发生天翻地覆改变，出现东升西降趋势，不仅有中国资金的北水，国际资金也有积极参与。 但过去6个月出现东升西降趋势，香港资本市场突发猛进，美国生物科技资本市场反而相对安静。 他以指数举例，香港生物科技ETF今年 ...